NLRP3-IN-28
NLRP3-IN-28 (compound N77) is a potent inhibitor of NLRP3. NLRP3-IN-28 inhibits Nigericin (HY-127019)-induced pyroptosis with an EC50 of 0.07μM. NLRP3-IN-28 alleviates the inflammatory reaction in vivo.
For research use only. We do not sell to patients.
- CAS No.: 2922814-80-8
- Formula: C12H9F3N2O3S
- Molecular Weight:318.27
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Chemical Information
-
CAS No. 2922814-80-8
-
Molecular Weight 318.27
-
Formula C12H9F3N2O3S
-
SMILES
O=S(C1=NN=C(C2=C(O)C=C(C(F)(F)F)C=C2)C=C1)(C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)